文献速递生殖医学

超声定义的子宫腺肌症亚型及其对冻融胚胎移植结局的影响:一项倾向性评分匹配队列研究

Ultrasound-defined adenomyosis subtypes and their impact on outcomes following frozen embryo transfer: a propensity score-matched cohort study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-10-13

这项回顾性单中心队列研究纳入2022年8月至2024年6月首次冻融胚胎移植(FET)且移植胚胎均为高质量的女性,按修订版MUSA标准用经阴道超声定义子宫腺肌症亚型,并以1:1倾向性评分匹配无子宫腺肌症的对照。结果显示子宫腺肌症组活产率显著低于对照(35.38% vs 45.16%),内型和混合型活产率降低更明显,早期妊娠丢失率升高。作者认为FET前超声表型分型可能有助于个体化管理,但需进一步前瞻性研究验证。

要点

  • 子宫腺肌症组活产率低于对照(35.38% vs 45.16%,P<0.001;OR 0.67,95%CI 0.55-0.81)。
  • 外型腺肌症活产率与对照无显著差异(45.80% vs 46.85%,P=0.795;OR 0.96,95%CI 0.74-1.24)。
  • 内型和混合型腺肌症活产率显著低于对照,混合型更低(18.09% vs 44.15%,P<0.001;OR 0.28,95%CI 0.17-0.45)。

核心结论

  • 子宫腺肌症,尤其是内型和混合型,与FET后活产率降低及达到临床妊娠者早期妊娠丢失风险升高相关。
  • FET前基于超声的子宫腺肌症表型分型可能支持个体化的辅助生殖技术管理。
  • 需要进一步的前瞻性研究来验证这些结果。

研究设计与样本

  • 回顾性、单中心队列研究,纳入2022年8月至2024年6月期间接受首次FET周期并以修订版MUSA标准行经阴道超声诊断子宫腺肌症的女性。
  • 仅纳入移植胚胎为高质量的FET周期。
  • 子宫腺肌症亚型定义:外型(局限于子宫外层肌层)、内型(累及内层肌层,对应子宫内膜-肌层交界区和/或中层肌层)和混合型(同时累及内层和外层肌层)。
  • 对照选自同一时期无超声证据的子宫腺肌症且接受FET的女性。
  • 采用患者年龄、体重指数、抗苗勒管激素水平、不孕类型、胚胎阶段、不孕原因、FET方案和移植胚胎数量进行1:1倾向性评分匹配。

主要发现

  • 子宫腺肌症组活产率显著低于对照(35.38% vs 45.16%,P<0.001;OR 0.67,95%CI 0.55-0.81)。
  • 外型腺肌症占病例50%以上,其活产率与匹配对照相当(45.80% vs 46.85%,P=0.795;OR 0.96,95%CI 0.74-1.24)。
  • 内型腺肌症活产率显著低于对照(27.44% vs 42.33%,P=0.002;OR 0.52,95%CI 0.34-0.77)。
  • 混合型腺肌症活产率更低(18.09% vs 44.15%,P<0.001;OR 0.28,95%CI 0.17-0.45)。
  • 子宫腺肌症组早期妊娠丢失率高于对照(占临床妊娠的22.25% vs 15.65%,P=0.011;OR 1.54,95%CI 1.10-2.15)。

关键数值与推荐

  • 主要结局活产定义为≥28周妊娠分娩至少一个活产婴儿。
  • 次要结局包括着床、临床妊娠、异位妊娠、早期妊娠丢失(<12周)、晚期妊娠丢失(12-28周)、多胎妊娠、早产(<37周)、低出生体重(<2500g)、胎儿生长受限、妊娠期高血压疾病、妊娠期糖尿病、前置胎盘、胎盘植入、胎盘早剥、胎膜早破和剖宫产分娩。
  • 子宫腺肌症亚型按修订版MUSA标准经超声定义:外型、内型和混合型。

临床怎么用

  • 作者认为FET前基于超声的子宫腺肌症表型分型可能支持个体化的辅助生殖技术管理。
  • 作者指出需要进一步的前瞻性研究来验证这些结果。

局限性

  • 原文未报告局限性,但结论指出需要进一步的前瞻性研究来验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of adenomyosis subtypes defined by ultrasound using the revised Morphological Uterus Sonographic Assessment (MUSA) criteria, with reproductive and obstetric outcomes following frozen embryo transfer (FET). METHODS: This retrospective, single-center cohort study included women who underwent their first FET cycle, as well as transvaginal ultrasound evaluation for the diagnosis of adenomyosis using the revised MUSA criteria, between August 2022 and June 2024. We included only FET cycles in which transferred embryos were of high quality. Adenomyosis subtypes were defined as follows: external (confined to the outer myometrium), internal (involving the inner myometrium, corresponding to the endometrial-myometrial junction, and/or the middle myometrium) and mixed (affecting both inner and outer myometrium). Controls were selected from women without ultrasound evidence of adenomyosis who underwent FET during the same period. Propensity score matching (1:1) was performed using patient age, body mass index, anti-Müllerian hormone level, infertility type, embryo stage, cause of infertility, FET protocol and number of embryos transferred. Comparative analyses were conducted to assess differences in reproductive and obstetric outcomes in women with adenomyosis, both overall and its subtypes, vs matched controls. The primary outcome was live birth, defined as delivery of at least one live infant at ≥ 28 weeks' gestation. Secondary outcomes were: implantation, clinical pregnancy, ectopic pregnancy, early pregnancy loss (< 12 weeks), late pregnancy loss (12-28 weeks), multiple pregnancy, preterm birth (< 37 weeks), low birth weight (< 2500 g), fetal growth restriction, hypertensive disorders of pregnancy, gestational diabetes mellitus, placenta previa, placenta accreta, placental abruption, premature rupture of membranes and delivery by Cesarean section. RESULTS: Of 4146 eligible women, 879 with adenomyosis and 879 matched controls without adenomyosis were included in the analysis. Their age ranged from 20 to 42 years. The rate of live birth was significantly lower in the group with adenomyosis compared to controls (35.38% vs 45.16%, P < 0.001; odds ratio (OR), 0.67 (95% CI, 0.55-0.81)). Women with external adenomyosis, accounting for over 50% of cases, had a live-birth rate comparable with that of their matched controls (45.80% vs 46.85%, P = 0.795; OR, 0.96 (95% CI 0.74-1.24)), whereas the live-birth rate was significantly lower for women with internal adenomyosis (27.44% vs 42.33%, P = 0.002; OR, 0.52 (95% CI, 0.34-0.77)) and even lower for those with mixed-type adenomyosis (18.09% vs 44.15%, P < 0.001; OR, 0.28 (95% CI, 0.17-0.45)) compared with controls. The rate of early pregnancy loss was higher in adenomyosis patients compared with controls (22.25% vs 15.65% of clinical pregnancies, P = 0.011; OR, 1.54 (95% CI, 1.10-2.15)). There were no significant differences in most of the other secondary outcomes in women with a live birth, between those with adenomyosis and controls. However, subgroup analysis revealed several significant associations between adenomyosis phenotypes, mainly internal and mixed-type adenomyosis, and specific obstetric outcomes. CONCLUSIONS: Adenomyosis, particularly internal and mixed-type, is associated with a reduced live-birth rate and an increased risk of early pregnancy loss in those achieving clinical pregnancy following FET. Ultrasound-based phenotyping of adenomyosis prior to FET may support individualized assisted reproductive technology management. Further prospective studies are needed to validate these results. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wang L, Zheng H, Weng C, et al. Ultrasound-defined adenomyosis subtypes and their impact on outcomes following frozen embryo transfer: a propensity score-matched cohort study. Ultrasound Obstet Gynecol. 2025. PMID: 41081491. doi:10.1002/uog.70102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。